Activity Description & Educational Objectives
In this activity, experts in leukemia management discuss recent data on novel and modern therapeutic options that have been validated or are being tested in patients with acute promyelocytic and myeloid leukemia.
Upon completion of this activity, participants should be better able to:
- Cite current recommendations for the management of acute promyelocytic and acute myeloid leukemia (APL and AML)
- Summarize and/or apply clinically relevant data on modified treatment options for newly diagnosed or relapsed APL
- Identify management strategies for challenging AML patient populations, including elderly patients, those with comorbid conditions, and those with high-risk or relapsed disease
- Demonstrate knowledge of the clinical potential of novel targeted and cytotoxic agents being tested in acute leukemia settings
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, oncologists, advanced practice oncology nurses, and other clinicians involved in the management of APL and AML.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: October 07, 2013 - October 06, 2014
Time to Complete: 45 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Farhad Ravandi, MD
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Farhad Ravandi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Genzyme Corporation, a Sanofi company; and Sunesis Pharmaceuticals.
Grant/Research Support from Bristol-Myers Squibb; Celgene Corporation; Merck & Co., Inc.; and Sunesis Pharmaceuticals.
Gary J. Schiller, MD
Professor, Department of Medicine
Director, Hematological Malignancy Stem Cell Transplantation Program
David Geffen School of Medicine at UCLA
Los Angeles, California
Gary J. Schiller, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Celator Pharmaceuticals; Clavis Pharma; Cyclacel Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Onyx; Ozmosis; Sunesis Pharmaceuticals; and Talon Therapeutics, Inc.
Shareholder in Amgen Inc. and Pfizer Inc.
Michael Evans, MD
Assistant Professor of Medicine
Penn State Milton S. Hershey Medical Center
Division of Hematology/Oncology
Michael Evans, MD, has a financial interest/relationship or affiliation in the form of:
Major Shareholder in Amgen Inc. and Celgene Corporation
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5420-14-T.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by educational grants from
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.